866-997-4948(US-Canada Toll Free)

Leiomyosarcoma - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 213 Pages

Leiomyosarcoma - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leiomyosarcoma - Pipeline Review, H2 2017, provides an overview of the Leiomyosarcoma (Oncology) pipeline landscape.

Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, if it presses on nerves or muscles and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure and radiation exposure. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leiomyosarcoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Leiomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leiomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Leiomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Leiomyosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Leiomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Leiomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Leiomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Leiomyosarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Leiomyosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Leiomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 5
Global Markets Direct Report Coverage 5
Leiomyosarcoma - Overview 6
Leiomyosarcoma - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 12
Leiomyosarcoma - Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Leiomyosarcoma - Companies Involved in Therapeutics Development 21
Advenchen Laboratories LLC 21
BeiGene Ltd 21
Cell Medica Ltd 22
Karyopharm Therapeutics Inc 22
Merck & Co Inc 23
Merck KGaA 23
Millennium Pharmaceuticals Inc 24
Mirati Therapeutics Inc 24
Novartis AG 25
Ono Pharmaceutical Co Ltd 25
Pfizer Inc 26
Vicore Pharma AB 26
Yooyoung Pharm Co Ltd 27
Leiomyosarcoma - Drug Profiles 28
AL-3818 - Drug Profile 28
avelumab - Drug Profile 31
axitinib - Drug Profile 42
baltaleucel-T - Drug Profile 48
BGB-290 - Drug Profile 50
C-21 - Drug Profile 52
Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 55
everolimus - Drug Profile 56
mocetinostat - Drug Profile 68
nivolumab - Drug Profile 73
pembrolizumab - Drug Profile 122
sapanisertib - Drug Profile 183
selinexor - Drug Profile 187
YYB-101 - Drug Profile 209
Leiomyosarcoma - Dormant Projects 210
Leiomyosarcoma - Discontinued Products 211
Appendix 212
Methodology 212
Coverage 212
Secondary Research 212
Primary Research 212
Expert Panel Validation 212
Contact Us 212
Disclaimer 213

List of Tables
Number of Products under Development for Leiomyosarcoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Leiomyosarcoma - Pipeline by Advenchen Laboratories LLC, H2 2017
Leiomyosarcoma - Pipeline by BeiGene Ltd, H2 2017
Leiomyosarcoma - Pipeline by Cell Medica Ltd, H2 2017
Leiomyosarcoma - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Leiomyosarcoma - Pipeline by Merck & Co Inc, H2 2017
Leiomyosarcoma - Pipeline by Merck KGaA, H2 2017
Leiomyosarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Leiomyosarcoma - Pipeline by Mirati Therapeutics Inc, H2 2017
Leiomyosarcoma - Pipeline by Novartis AG, H2 2017
Leiomyosarcoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Leiomyosarcoma - Pipeline by Pfizer Inc, H2 2017
Leiomyosarcoma - Pipeline by Vicore Pharma AB, H2 2017
Leiomyosarcoma - Pipeline by Yooyoung Pharm Co Ltd, H2 2017
Leiomyosarcoma - Dormant Projects, H2 2017
Leiomyosarcoma - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Leiomyosarcoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *